Table 2.
IL-6 |
IL-8 |
MCP-1 |
||||
---|---|---|---|---|---|---|
Coefficient | Estimates | P | Estimates | P | Estimates | P |
(Intercept) | −1.57 (−2.56–−0.57) |
0.002 | 1.14 (0.46–1.82) |
0.001 | 5.13 (4.67–5.59) |
<0.001 |
Age | 0.01 (0.00–0.02) |
0.032 | 0.01 (0.00–0.01) |
0.025 | 0.00 (−0.00–0.01) |
0.149 |
Male | 0.43 (0.06–0.79) |
0.023 | 0.15 (−0.09–0.39) |
0.219 | 0.09 (−0.08–0.26) |
0.299 |
Body mass index | 0.01 (−0.02–0.03) |
0.518 | 0.01 (−0.01–0.03) |
0.249 | 0.01 (−0.00–0.02) |
0.226 |
Time from pain onset (days) | 0.01 (−0.15–0.16) |
0.947 | 0.00 (−0.14–0.14) |
0.980 | −0.04 (−0.12–0.03) |
0.275 |
AP severity | ||||||
MAP | 2.01 (1.33–2.69) |
<0.001 | 1.17 (0.65–1.69) |
<0.001 | 0.64 (0.32–0.96) |
<0.001 |
MSAP | 3.82 (3.00–4.64) |
<0.001 | 1.22 (0.58–1.86) |
<0.001 | 0.61 (0.22–1.00) |
0.002 |
SAP | 6.28 (5.45–7.10) |
<0.001 | 3.56 (2.93–4.20) |
<0.001 | 1.85 (1.45–2.24) |
<0.001 |
Time by AP severity interaction | ||||||
MAP | 0.01 (−0.19–0.20) |
0.940 | −0.05 (−0.23–0.12) |
0.570 | −0.13 (−0.23–−0.03) |
0.008 |
MSAP | −0.18 (−0.39–0.04) |
0.112 | 0.00 (−0.19–0.20) |
0.969 | −0.03 (−0.14–0.08) |
0.641 |
SAP | −0.30 (−0.50–−0.09) |
0.005 | −0.28 (−0.47–−0.10) |
0.003 | −0.08 (−0.18–0.03) |
0.147 |
Random effects | ||||||
σ2 | 0.52 | 0.43 | 0.13 | |||
τ00 | 1.09 Person.ID | 0.38 Person.ID | 0.21 Person.ID | |||
ICC | 0.68 | 0.47 | 0.62 | |||
N | 165 Person.ID | 165 Person.ID | 165 Person.ID | |||
Observations | 439 | 439 | 438 | |||
Marginal R2 /Conditional R2 | 0.689/0.900 | 0.527/0.748 | 0.514/0.815 |
All cytokine concentrations were transformed on a log scale before mixed model estimation. All models use the control series as baseline. A significant result in AP severity denotes a log scale shift from baseline control levels for that category. A significant result in Time by AP Severity denotes a significant change (±) in slope from the baseline control slope. Significance P values with P < 0.05 are in bold for emphasis. IL-8, interleukin-8; IL-6, interleukin-6; MCP-1, monocyte chemoattractant protein-1; MAP, mild acute pancreatitis; MSAP, moderately severe acute pancreatitis; SAP, severe acute pancreatitis.